Quantinno Capital Management LP Has $2.52 Million Stock Holdings in Caris Life Sciences, Inc. $CAI

Quantinno Capital Management LP grew its position in Caris Life Sciences, Inc. (NASDAQ:CAI) by 117.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 140,909 shares of the company’s stock after buying an additional 75,987 shares during the period. Quantinno Capital Management LP’s holdings in Caris Life Sciences were worth $2,519,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Global Retirement Partners LLC increased its position in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares during the period. PNC Financial Services Group Inc. lifted its position in Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after purchasing an additional 1,469 shares during the period. Fifth Third Bancorp bought a new position in shares of Caris Life Sciences in the 1st quarter valued at about $31,000. Sterling Capital Management LLC boosted its stake in shares of Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Strs Ohio grew its position in shares of Caris Life Sciences by 301.3% during the 1st quarter. Strs Ohio now owns 2,179 shares of the company’s stock worth $39,000 after buying an additional 1,636 shares during the period.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, Director Jon Halbert acquired 68,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $14.56 per share, with a total value of $990,080.00. Following the purchase, the director owned 704,598 shares of the company’s stock, valued at $10,258,946.88. This represents a 10.68% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 50.00% of the stock is currently owned by corporate insiders.

Caris Life Sciences Price Performance

Shares of NASDAQ:CAI opened at $22.74 on Monday. The company has a 50 day moving average price of $17.22 and a two-hundred day moving average price of $18.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.88 and a current ratio of 5.53. The company has a market capitalization of $6.43 billion, a PE ratio of 63.17 and a beta of 0.68. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50.

Caris Life Sciences announced that its board has approved a share buyback program on Monday, June 8th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 2.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CAI. Jefferies Financial Group assumed coverage on shares of Caris Life Sciences in a report on Monday, April 13th. They issued a “buy” rating and a $28.00 price objective on the stock. Wolfe Research cut shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Robert W. Baird set a $22.00 price target on Caris Life Sciences in a research report on Friday, May 8th. New Street Research began coverage on Caris Life Sciences in a research note on Friday, May 8th. They set a “market perform” rating for the company. Finally, JPMorgan Chase & Co. dropped their price objective on Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Caris Life Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $26.33.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.